Clinuvel Pharmaceuticals Ltd
F:UR9A
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Clinuvel Pharmaceuticals Ltd
F:UR9A
|
AU |
|
Zhejiang EV-Tech Co Ltd
SZSE:301607
|
CN |
|
ABC Arbitrage SA
OTC:ABCCF
|
FR |
|
C
|
Churchill Downs Inc
SWB:CHR
|
US |
|
T
|
Tekna Holding ASA
OSE:TEKNA
|
NO |
|
Henry Schein Inc
NASDAQ:HSIC
|
US |
|
Phunware Inc
NASDAQ:PHUN
|
US |
|
Erdene Resource Development Corp
F:E8K
|
CA |
|
TechnipFMC PLC
NYSE:FTI
|
UK |
|
Esso Societe Anonyme Francaise SA
F:EH8
|
FR |
Wall St Price Targets
UR9A Price Targets Summary
Clinuvel Pharmaceuticals Ltd
According to Wall Street analysts, the average 1-year price target for UR9A is 12.6 EUR with a low forecast of 5.76 EUR and a high forecast of 25.65 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is UR9A's stock price target?
Price Target
12.6
EUR
According to Wall Street analysts, the average 1-year price target for UR9A is 12.6 EUR with a low forecast of 5.76 EUR and a high forecast of 25.65 EUR.
What is the Revenue forecast for Clinuvel Pharmaceuticals Ltd?
Projected CAGR
8%
Over the last 13 years, the compound annual growth rate for Revenue has been 39%. The projected CAGR for the next 8 years is 8%.
What is the Gross Profit forecast for Clinuvel Pharmaceuticals Ltd?
Projected CAGR
8%
The compound annual growth rate for Gross Profit over the next 8 years is 8%.
What is the Operating Income forecast for Clinuvel Pharmaceuticals Ltd?
Projected CAGR
9%
The compound annual growth rate for Operating Income over the next 8 years is 9%.
What is the Pre-Tax Income forecast for Clinuvel Pharmaceuticals Ltd?
Projected CAGR
12%
The compound annual growth rate for Pre-Tax Income over the next 4 years is 12%.
What is the Net Income forecast for Clinuvel Pharmaceuticals Ltd?
Projected CAGR
11%
The compound annual growth rate for Net Income over the next 8 years is 11%.
